| What Will NicOx Do Next Following FDA Let-Down? EP Vantage submits:It always looked as if it might be a bit of a stretch and Wednesday an FDA advisory committee almost certainly snapped any hopes that NicOx (NICXF.PK) would garner FDA approval for its osteoarthritis drug naproxcinod by the expected PDUFA deadline of July 24. While the company is still pointing to the fact that the FDA does not have to follow the recommendations of its advisory committees, and certainly recent decisions such as the rejection of InterMune’s (ITMN) pirfenidone have demonstrated that it can overturn opinions, the pretty clear vote of 16-1 against approval which triggered a 45% plunge in the shares Thursday to €2.90 indicates that few others think a thumbs up is likely.Complete Story » seekingalpha.com |
Early Alzheimer's Diagnosis Yields Savings Early diagnosis of cognitive impairment can yield substantial savings in medical costs for Alzheimer's patients, according to a new study. online.wsj.com |
Medical Marijuana on the Job The difference between federal and state laws on medical marijuana use is making things complicated for employers. online.wsj.com |
A Different Kind of Eyeglasses Zoom Focus Eyewear wins the Silver award in The Wall Street Journal's 2010 Technology Innovation Awards for eyeglasses that the wearer can manually adjust to give clear vision at any distance online.wsj.com |
FDA to Reiterate Warning on Plavix, Prilosec The FDA said it plans to reiterate its warning that patients taking anticlotting drug Plavix should avoid also taking the heartburn drug Prilosec. online.wsj.com |